Wednesday, November 29, 2006

New safety information about Evra (norelgestromin and ethinyl estradiol) Transdermal System

From Health Canada:
Following discussions with Health Canada, Janssen-Ortho Inc. would like to update you on important new safety information pertaining to EVRA*. The EVRA* transdermal system marketed in Canada contains 6.0 mg norelgestromin (NGMN) and 0.60 mg ethinyl estradiol (EE) and is indicated for contraception.
For Health Professionals
For the Public

No comments: